

文献検索式

MEDLINE (Dialog)

PubMed

I. 対象データ：2012年1月1日～2016年6月30日

疾患：肝細胞癌に限定

言語：英語文献に限定

新設された CQ については原則 1982 年 1 月 1 日～2016 年 6 月 30 日までの文献を検索したが、
CQ によっては古い文献を検索する意義の乏しい CQ もあり、その場合は検索対象期間を記載
した

II. 検索式

【第 1 章 診断およびサーベイランス】

CQ1：サーベイランスは、推奨されるか？ [PubMed]

CQ2：サーベイランスは、どのような対象にどのような方法で行うか？ [PubMed]

#1 "Liver neoplasms"[MH] AND (surveillance[tiab] OR screening[tiab]) AND 2012/1/1:2016/06/30[dp]
AND Eng[la] AND hasabstract[text] NOT "case reports"[pt]

CQ3：肝細胞癌の診断に有用な腫瘍マーカーは何か？ [PubMed]

#1 "Carcinoma, hepatocellular/diagnosis"[majr] AND "sensitivity and specificity"[MH] AND "biomarkers,
Tumor"[MH] AND 2000/1/1:2016/6/30[dp] AND hasabstract[text] Eng[la] NOT "case reports"[pt]
(検索対象期間 2000 年 1 月 1 日～2016 年 6 月 30 日)

CQ4：肝細胞癌の診断に有用な腫瘍マーカーは何か？ [PubMed]

CQ5：腫瘍マーカーの測定は、肝細胞癌の治療効果判定の指標として有効か？ [PubMed]

#1 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular carcinoma"[tiab] OR "hepatoma"[tiab] OR
"liver cancer"[tiab] OR HCC[tiab]) AND (alpha-fetoprotein[tiab] OR alphafetoprotein[tiab] OR
AFP[tiab] OR αFP[tiab] OR PIVKA[tiab] OR "protein induced by vitamin K absence or antagonist
II"[tiab] OR "des-gamma-carboxy prothrombin"[tiab] OR DCP[tiab] OR
acarboxyprothrombin[Supplementary Concept] OR "lens culinaris agglutinin-reactive alpha-
fetoprotein"[tiab] OR "core-fucosylated alpha fetoprotein"[tiab] OR "AFP-L3"[tiab] OR "glypican-
3"[tiab] OR GPC3[tiab] OR GP3[tiab]) AND "sensitivity"[tiab] AND "specificity"[tiab] AND
2000/1/1:2016/6/30[dp] AND Eng[la] AND hasabstract[text] NOT "case reports"[pt]
(検索対象期間 2000 年 1 月 1 日～2016 年 6 月 30 日)

CQ6：肝細胞癌の高危険群において、典型的肝細胞癌の診断に診断能が高い検査は何か？ [MEDLINE]

L1 CARCINOMA, HEPATOCELLULAR/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR
HAEPATO? OR LIVER?)(W)(CELL# OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR
TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA#)/TI OR (HCC OR HCCS)/TI AND
LIVER NEOPLASMS+NT/CT

L2 L1/HUMAN OR (L1 NOT ANIMALS)

L3 L2/ENG

L4 L3 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS

- L5 QUE DIAGNOSIS+NT/CT OR (DI OR RA OR RI OR US)/CT OR (DIAGNOS? OR DETECT? OR IDENTI? OR TEST? OR IMAG?)/TI
- L6 "SENSITIVITY AND SPECIFICITY"+NT/CT OR SENSITIVIT? OR SPECIFICIT? OR ACCURAC? OR ROC
- L7 L4 AND L5 AND L6
- L8 (USEFUL? OR EFFICAC? OR EFFECTIV?)/TI
- L9 MT/CT
- L10 (L7 AND L8) OR (L7 AND L9)
- L11 QUE DIAGNOSTIC IMAGING+NT/CT OR IMAGE PROCESSING, COMPUTER-ASSISTED+NT/CT OR TOMOGRAPH? OR IMAG? OR ANGIOGRAPHY+NT/CT OR ARTERIOGRAPH? OR ANGIOGRAPH? OR AORTOGRAP? OR CINEANGIOGRAPH? OR PHLEBOGRAPH? OR PORTOGRAPH? OR ULTRASONOGRAPHY+NT/CT OR ULTRASON?
- L12 QUE (ULTRASONICS+NT OR DIAGNOSTIC TECHNIQUES, RADIOISOTOPE+NT OR RADIONUCLIDE IMAGING+NT OR US OR RA OR RI)/CT OR NUCLEAR MEDICINE+NT/CT AND DIAGNOSIS+NT/CT OR ECHOGRAPH? OR ECHO# OR SONOGR? OR ULTRASOUND? OR NUCLEAR(1W)MEDICINE(2A)DIAGNOSIS? OR SCINT? OR MRI OR SPECT OR PET OR CT
- L13 CONTRAST MEDIA+NT/CT OR (CONTRAST OR RADIOPAQUE)(1A)(MEDIA? OR DYE? OR MATERIAL? OR AGENT?)
- L14 L4 AND (L11 OR L12) AND L13
- L15 L14 AND L6
- L16 (CONTRAST? OR IODINE? OR GD)/TI AND L14
- L17 L15 OR L16
- L18 BIOMARKERS, TUMOR+NT/CT OR ?MARKER?(3A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)
- L19 L4 AND (L11 OR L12) AND L18
- L20 L10 OR L17 OR L19
- L21 L20 AND *DIAGNOSIS+NT/CT AND *CARCINOMA, HEPATOCELLULAR/CT(L)DI./CT

CQ7 : Dynamic CT／MRI で典型的所見を示さない肝結節の精査は、何 cm 以上から行うのが望ましいか？ [PubMed]

#1 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[TIAB] OR "HCC"[tiab]) AND (biopsy[MH] OR hepatectomy[MH] OR resection[tiab] OR transplantation[tiab] OR pathology[MH] OR pathology[tiab] OR pathologic[tiab] OR pathological[tiab] OR pathologically[tiab] OR histology[tiab] OR histologic[tiab]) AND ("MRI"[tiab] OR "MR"[tiab] OR "CT"[tiab] OR ultrasonography[tiab] OR ultrasographic[tiab] OR ultrasound[tiab]) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

CQ8 : 肝硬変患者における早期肝細胞癌の検出において、診断能が高い検査は何か？ [MEDLINE]

- L1 LIVER CIRRHOSIS+NT/CT OR ((LIVER OR LIVERS OR HEPATIC)(3A)CIRRHO? OR CHRONIC?(3A)LIVER(2W)(DISEASE? OR DISORDER?))/TI
- L2 ((WELL OR TERMINAL?)(W)DIFFERENT? OR SMALL? OR HYPOVASCULAR? OR ADENOMATOUS?(3A)HYPERPLASI? OR DYSPLASTI?(3A)NODUL?)/TI
- L3 (BORDERLIN? OR NODUL?)/TI

L4 INTERNATIONAL?(3A)CONSENS?(3A)GROUP?(3A)HEPATOCEL?(W)NEOPLAS?
L5 FOCAL NODULAR HYPERPLASIA+NT/CT
L6 CARCINOMA, HEPATOCELLULAR/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL# OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA#)/TI OR (HCC OR HCCS)/TI AND LIVER NEOPLASMS+NT/CT
L7 EARLY(4A)(CARCINOM? OR HCC OR HEPATOM? OR NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR HAEPATOM? OR HCCS)
L8 QUE DISEASE PROGRESSION+NT/CT
L9 QUE DI/CT OR US/CT OR RA/CT OR RI/CT OR DIAGNOSTIC IMAGING+NT/CT OR DIAGNOSIS+NT/CT
L10 QUE DIAGNOS?/TI
L11 ANGIOGRAPHY+NT/CT OR IMAGE PROCESSING, COMPUTER-ASSISTED+NT/CT OR ULTRASONOGRAPHY+NT/CT OR ULTRASONICS+NT/CT OR (NUCLEAR MEDICINE+NT/CT AND DIAGNOSIS+NT/CT) OR DIAGNOSTIC TECHNIQUES, RADIOISOTOPE+NT/CT
L12 QUE CT OR ULTRASO? OR IMAG? OR IMAGING? OR TOMOGRA? OR MDCT OR NMR OR MRI OR SPECT OR PET OR ECHOGRAPH? OR ECHO# OR SONOGR? OR NUCLEAR(1W)MEDICINE(2A)DIAGNOSIS? OR SCINT?
L13 QUE ARTERIOGRAPH? OR ANGIOGRAPH? OR AORTOGRAP? OR CINEANGIOGRAPH? OR PHLEBOGRAPH? OR PORTOGRAPH? OR CTHA OR CTAP
L14 QUE (L11 OR L12 OR L13)
L15 QUE OUTCOME?/TI
L16 QUE SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC
L17 (L1 OR L2 OR L3 OR L4 OR L5) AND (L6 OR L7 OR L8) AND (L9 OR L10 OR L14)
L18 L17 AND (LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?)/TI AND L15
L19 (DIAGNOS? OR IDENTI? OR DETECT? OR ASSESS? OR EVALUAT? OR MANAGE?)/TI
L20 (LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?)/TI AND L17 AND (L19 or L12/TI or L13/TI)
L21 L20 AND L16
L22 L21 OR L18
L23 PREEXAMINAT? OR PRE(1W)EXAMINAT? OR PREDIAGNOS? OR PRETREATMENT? OR PRETHERAP? OR PRE(1W)(DIAGNO? OR TREATMENT? OR THERAP?)
L24 L6 AND L14 AND L23
L25 ((HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL# OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?) OR HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
L26 L6 AND L25 AND (L12/TI OR L13/TI)
L27 L24 OR L26
L28 CONTRAST MEDIA+NT/CT
L29 (CONTRAST OR RADIOPAQUE)(1A)(MEDIA? OR DYE? OR MATERIAL? OR AGENT?)
L30 L6 AND (L9 OR L10 OR L14) AND (L28 OR L29)

L31 L16 AND L30
 L32 (CONTRAST? OR IODINE? OR GD)/TI AND L30
 L33 L31 OR L32
 L34 L6 AND (L9 OR L10) AND L14 AND (L28 OR L29)
 L35 L34 AND (*DIAGNOSTIC IMAGING+NT/CT OR *DIAGNOSIS+NT/CT) AND L11/MAJ
 L36 L33 OR L35
 L37 L22 OR L27 OR L36
 L38 L37/HUMAN OR (L37 NOT ANIMALS)
 L39 L38/ENG
 L40 L39 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS
 L41 L40 AND (L1 OR L7 OR (WELL OR TERMINAL?)(W)DIFFERENT?)

CQ9 : 腎機能および肝機能低下患者における肝腫瘍の診断には, どの検査法が有用か? [MEDLINE]

L1 (LIVER or HEPATIC? or HEPATO? or KIDNEY or RENAL or CK or CREATIN?)(3A)(FUNCTION? or IMPAIR? or FAILUR? or INSUFFICIEN? or DETERIORA? or EXACERBAT? or DYSFUNCT? or HYPOFUNCT? or LESION? or DISORDER? or DAMAGE? or ABNORMAL?)
 L2 NEPHROPATH? OR CIRRHOSIS? OR NEPHRITIS?
 L3 JAUNDIC? OR HYPERBIL? OR (BIL OR BILI?)(3A)(RISE? OR RISING? OR ELEVAT? OR HIGH? OR INCREASES?)
 L4 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
 L5 GD()EOB()DTPA or GADOXETIC?(3W)ENHANCE?(3W)(MRI OR MR)
 L6 CONTRAST?(3W)(CT OR MR OR NMR OR MRI OR ULTRASON?)
 L7 CTAP OR CTHA OR IODI?(3A)CONTRAST? OR GD OR GADOXETIC? OR DTPA OR EOB OR SONAZOID?
 L8 CONTRAST?(3W)ENHANC? OR ENHANC?(3A)(CT OR MR OR NMR OR MRI OR ULTRASON?)
 L9 QUE DI/CT or DIAGNOSIS+NT/CT or RA/CT or RI/CT or US/CT
 L10 (L1 or L2 or L3 or L4) and L5/TI
 L11 (L1 or L2 or L3) and L4 and (L5/TI or L6/TI or L7/TI or L8/TI)
 L12 (HEPATIC?/TI OR HEPATO?/TI OR LIVER?/TI OR L1/TI or L2/TI or L3/TI) AND L11
 L13 L12 and L9
 L14 L13 or L10
 L15 L14/HUMAN or (L14 NOT ANIMALS)
 L16 L15 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
 L17 L16/ENG
 L18 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
 L19 L17 NOT L18
 L20 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT

L21 L17 and L20

L22 L19 or L21

CQ10 : 肝細胞癌の病期診断に頭部 MRI, 胸部 CT, 骨シンチグラフィー, FDG-PET は必要か ?

[MEDLINE]

L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT

L2 L1/HUMAN or (L1 NOT ANIMALS)

L3 L2/ENG

L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS

L5 QUE DIAGNOSTIC IMAGING+NT/CT or IMAGE PROCESSING, COMPUTER-ASSISTED+NT/CT or TOMOGRAPH? or IMAG? or ANGIOGRAPHY+NT/CT or ARTERIOGRAPH? or ANGIOGRAPH? or AORTOGRAP? or CINEANGIOGRAPH? or PHLEBOGRAPH? or PORTOGRAPH? or ULTRASONOGRAPHY+NT/CT or ULTRASON?

L6 QUE ECHOGRAPH? or ECHO# or SONOGR? or ULTRASOUND? or ULTRASONICS+NT/CT or US/CT

L7 QUE NUCLEAR(1W)MEDICINE(2A)DIAGNOSIS? or NUCLEAR MEDICINE+NT/CT and DIAGNOSIS+NT/CT or DIAGNOSTIC TECHNIQUES, RADIOISOTOPE+NT/CT or RADIONUCLIDE IMAGING+NT/CT or SCINT? or MRI or SPECT or PET or CT or (RA or RI)/CT

L8 STAGE? OR STAGING? OR METASTA? OR INFILTRA? OR INVASI? OR INVOLVE?

L9 L4 and (L5 or L6 or L7) and L8

L10 QUE CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING? OR DETECT? OR DIAGNOS?

L11 L9 and (L8/TI or L10/TI) and (HEPATO? OR HEPATIC? OR LIVER?)/TI

L12 L11 and (L8/TI or DETECT?/TI or DIAGNO?/TI)

L13 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI

L14 L12 NOT L13

L15 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT

L16 L12 and L15

L17 L16 or L14

【第2章 治療アルゴリズム】

CQ11 : 単発肝細胞癌に対し, 推奨できる治療法は何か ? [MEDLINE]

L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI

L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS

L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)

L4 L3 AND EN/LA

- L5 (SMALL OR SINGL? OR SOLITARY)(4A)(HCC OR HCCS OR HEPATOCEL? OR TUMOR? OR TUMOUR? OR CARCINOM? OR CANCER?)
- L6 (CHILD(W)PUGH OR CLASS)(2W)('A' OR 'B') OR (TUMOR? OR TUMOUR?)(2A)(NUMBER? OR SIZE?) OR LIVER?(2W)DAMAGE?
- L7 HEPATECTOMY+AUTO/CT OR HEPATECTOM? OR RESECT? OR EXCISION?
- L8 RADIOFREQUEN? OR RFA
- L9 TREATMENT(3A)(ALGORITHM? OR ALLOCAT? OR SELECT?)
- L10 L4 AND (L5 OR L6) AND L7 AND L8
- L11 L4 AND (L5 OR L6) AND (L7 OR L8) AND L9
- L12 (RADIOFREQUEN? OR RFA OR ABLAT? OR HEPATECTOM? OR RESECT? OR EXCISION?)/TI AND L10
- L13 L11 OR L12
- L14 (HEPATOCELL? OR HAEPATOCELL? OR HCC OR HCCS)/TI AND L13

CQ12 : 2,3 個肝細胞癌に対し、推奨できる治療法は何か? [MEDLINE]

- L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS
- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 (TWO OR THREE? OR '2' OR '3')(4A)(HCC OR HCCS OR HEPATOCEL? OR TUMOR? OR TUMOUR? OR CARCINOM? OR CANCER?)
- L6 (CHILD(W)PUGH OR CLASS)(2W)('A' OR 'B') OR (TUMOR? OR TUMOUR?)(2A)(NUMBER? OR SIZE?) OR LIVER?(2W)DAMAGE?
- L7 HEPATECTOMY+AUTO/CT OR HEPATECTOM? OR RESECT? OR EXCISION?
- L8 RADIOFREQUEN? OR RFA
- L9 CHEMOEMBOLIZATION, THERAPEUTIC+AUTO/CT
- L10 TACE OR TAE OR (TRANSARTER? OR TRANSCATHETER? OR (TRANS OR TRANSCATHETER?)(W)ARTERI?)(2W)(CHEMOEMBOLI? OR EMBOLI?)
- L11 L4 AND (L5 OR L6) AND (L7 AND (L8 OR L9 OR L10) OR L8 AND (L9 OR L10))
- L12 (HEPATECTOM? OR RESECT? OR RADIOFREQUEN? OR ABLAT? OR RFA OR TACE OR TAE OR CHEMOEMBOLI? OR EMBOLI?)/TI AND L11
- L13 L4 AND (L5 OR L6) AND (L7 OR L8 OR L9 OR L10) AND (HEPATECTOM? OR RESECT? OR EXCISION? OR RADIOFREQUEN? OR ABLAT? OR RFA OR TACE OR TAE OR CHEMOEMBOLI? OR EMBOLI?)/TI AND TREATMENT(3A)(ALGORITHM? OR ALLOCAT? OR SELECT?)
- L14 L12 OR L13
- L15 (HEPATOCELL? OR HAEPATOCELL? OR HCC OR HCCS)/TI AND L14

CQ13 : 4 個以上肝細胞癌に対し、推奨できる治療法は何か? [MEDLINE]

- L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS

- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 (FOUR OR '4' OR MULTIPL? OR ADVANCE? OR UNRESECT?)(4A)(HCC OR HCCS OR HEPATOCEL? OR TUMOR? OR TUMOUR? OR CARCINOM? OR CANCER?)
- L6 L4 AND L5
- L7 CHEMOEMBOLIZATION, THERAPEUTIC+AUTO/CT
- L8 TACE OR TAE OR (TRANSARTER? OR TRANSCATHETER? OR (TRANS OR TRANSCATHETER?)(W)ARTERI?)(2W)(CHEMOEMBOLI? OR EMBOLI?)
- L9 SORAFENIB? OR MOLECUL?(2W)TARGET? OR (MULTIKINASE? OR KINASE?)(2A)INHIBITOR?
- L10 HEPATIC?(3A)ARTER?(3A)INFUS? OR INFUSIONS, INTRA-ARTERIAL+AUTO/CT
- L11 L6 AND ((L7 OR L8 OR L9 OR L10))
- L12 L11 AND TREATMENT(3A)(ALGORITH? OR ALLOCAT? OR SELECT?)
- L13 L11 AND (L7 OR L8) AND (L9 OR L10)
- L14 L11 AND (SORAFENIB? OR MOLECUL?(2W)TARGET? OR (MULTIKINASE? OR KINASE?)(2A)INHIBITOR? OR HEPATIC?(3A)ARTER?(3A)INFUS? OR TACE OR TAE OR CHEMOEMBOLI? OR EMBOLI?)/TI
- L15 NEOPLASM STAGING+AUTO/CT AND L14
- L16 L12 OR L13 OR L15
- L17 (HEPATOCELL? OR HAEPATOCELL? OR HCC OR HCCS)/TI AND L16

CQ14 : 肝障害度 C(Child-Pugh 分類 C)の肝細胞癌に対し、推奨できる治療法は何か? [MEDLINE]

- L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS
- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 LIVER CIRRHOSIS+NT/CT(L)CO/CT OR CIRRHO?/TI
- L6 (CHILD(W)PUGH OR CLASS)(2W)'C'
- L7 END(1W)STAGE(1W)(LIVER? OR HEPAT?)
- L8 L4 AND ((L5 OR L6 OR L7))
- L9 *CARCINOMA, HEPATOCELLULAR+AUTO/CT(L)(DT OR TH OR RT OR TR OR SU)/CT
- L10 L8 AND L9
- L11 PROGNOSIS+NT/CT OR PROGNOS? OR SURVIV? OR MORTALI? OR OUTCOME? OR CONSEQUENC?
- L12 CARCINOMA, HEPATOCELLULAR+AUTO/CT(L)MO/CT
- L13 L10 AND L11 AND L12
- L14 (HEPATOCELL? OR HAEPATOCELL? OR HCC OR HCCS)/TI AND L13

CQ15-1 : 肝細胞癌の骨転移・脳転移に対して放射線治療は有効か? [MEDLINE]

- L1 BRAIN NEOPLASMS+NT/CT(L)SECONDARY/CT OR LUNG NEOPLASMS+NT/CT(L)SECONDARY/CT OR BONE NEOPLASMS+NT/CT(L)SECONDARY/CT OR (?BRAIN? OR ?CRANIAL? OR ?CEREBR? OR LUNG OR PULMON? OR BONE OR BONY OR OSSEOUS? OR OSTEO?)(3A)METASTA?/TI
- L2 L1 AND PY=>2011 AND 20120101-20160630/UP NOT EPUB?/FS

- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 *RADIOTHERAPY+NT/CT OR (RADIOTHERA? OR (RADIAT? OR IRRADIAT?))(2A)THERAP? OR RADIOSURG? OR CHEMORADIO? OR RADIOCHEMO?)/TI
- L6 *NEOPLASMS+NT/CT(L)RT/CT
- L7 L4 AND (L5 OR L6)
- L8 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?))(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L9 L7 AND L8
- L10 (?BRAIN? OR ?CRANIAL? OR ?CEREBR? OR LUNG OR PULMON? OR BONE OR BONY OR OSSEOUS? OR OSTEO?)(3A)METASTA?/TI
- L11 L7 AND L10
- L12 META-ANALYSIS/DT OR (META(1W)ANALY? OR METAANAL? OR METANAL? OR SYSTEMATIC?(2A)(REVIEW? OR OVERVIEW?) OR INTEGRATIVE?(1A)RESEARCH?(1A)REVIEW? OR RESEARCH?(1A)INTEGRATION?)/TI
- L13 RANDOMIZED CONTROLLED TRIAL/DT OR PRAGMATIC CLINICAL TRIAL/DT OR RANDOM ALLOCATION+NT/CT OR (SINGLE-BLIND METHOD+NT OR DOUBLE-BLIND METHOD+NT)/CT OR ((SINGL? OR DOUBLE? OR TREBL? OR TRIPL?)(W)(BLIND? OR MASK?) OR RANDOM? OR PRAGMATIC?(3W)(STUD? OR TRIAL? OR TEST?))/TI
- L14 L11 AND (L12 OR L13)
- L15 L9 OR L14

CQ15-2 : 肝細胞癌の肝外転移(肺転移, 副腎転移, リンパ節転移, 播種) に対する有効な治療法は何か? [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?))(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS
- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 LYMPHATIC METASTASIS+AUTO/CT OR ADRENAL GLAND NEOPLASMS+NT/CT(L)SECONDARY/CT OR LUNG NEOPLASMS+NT/CT(L)SECONDARY/CT OR PERITONEAL NEOPLASMS+AUTO/CT(L)SECONDARY/CT OR NEOPLASM SEEDING+AUTO/CT OR NEOPLASM INVASIVENESS+NT/CT
- L6 ((EXTRAHEPATIC? OR EXTRA(1W)HEPATIC? OR LYMPH? OR LUNG? OR PULMONARY? OR PERITONE? OR ADRENAL?)(3A)METASTA? OR INVASIV? OR SEEDING? OR INFILTRAT?)/TI
- L7 L4 AND (L5 OR L6)
- L8 L7 AND NEOPLASMS+NT/CT(L)(SU OR TR OR TH OR DT)/CT
- L9 RADIOLOGY, INTERVENTIONAL+AUTO/CT OR (IVR OR INTERVENTIONAL?(3A)RADIOL?)/TI
- L10 ANTINEOPLASTIC PROTOCOLS+NT/CT
- L11 ADRENALECTOMY+AUTO/CT OR LYMPH NODE EXCISION+AUTO/CT OR

METASTASECTOMY+AUTO/CT

- L12 CHEMOEMBOLIZATION, THERAPEUTIC+AUTO/CT
- L13 (TACE OR TAE OR (TRANSARTER? OR TRANSCATHETER? OR (TRANS OR TRANSCATHETER?)(W)ARTERI?)(2W)(CHEMOEMBOLI? OR EMBOLI?))/TI
- L14 (RADIOFREQUEN? OR RFA OR CRYOABLAT? OR CRYOSURG? OR PERCUTANEOU?(3A)VERTEBROPLAST?)/TI
- L15 ULTRASONIC THERAPY+NT/CT OR (HIGH(3A)INTENSITY(3A)FOCUSED(3A)ULTRASOUND? OR HIFU)/TI
- L16 (RESECT? OR EXCIS? OR METASTASECTOM? OR METASTATECTOM? OR ADRENALECTOM? OR CHEMOTHER? OR INTERNAL?)/TI
- L17 L8 AND ((L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16))
- L18 (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L19 L17 AND L18

CQ16 : 脈管侵襲陽性肝細胞癌に対する有効な治療は何か？ [MEDLINE]

- L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS
- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 NEOPLASM STAGING+AUTO/CT
- L6 ((VESSEL? OR VASCULAR? OR LYMPHOVASCULAR? OR MACROVASCULAR? OR PORTAL?)(3A)(INVAS? OR INFILTRAT?) OR ADVANCE?)(4A)(HCC OR HCCS OR HEPATOCEL? OR TUMOR? OR TUMOUR? OR CARCINOM? OR CANCER?)
- L7 PORTAL?(3A)VEIN?(3A)THROMBOS?
- L8 L4 AND L5 AND (L6 OR L7)
- L9 L4 AND (VESSEL? OR VASCULAR? OR LYMPHOVASCULAR? OR MACROVASCULAR? OR PORTAL?)(3A)(INVAS? OR INFILTRAT?)/TI
- L10 L8 OR L9
- L11 HEPATECTOMY+AUTO/CT OR HEPATECTOM? OR RESECT? OR EXCISION?
- L12 CHEMOTHERAP?/TI OR ANTINEOPLASTIC AGENTS+NT/CT(L)(TU OR AD) OR CARCINOMA, HEPATOCELLULAR+AUTO/CT(L)DT/CT
- L13 RADIOTHERAP?/TI OR (RADIAT? OR IRRADIAT?)(2A)THERAP?/TI OR CARCINOMA, HEPATOCELLULAR+AUTO/CT(L)RT/CT OR RADIOTHERAPY+NT/CT
- L14 TREATMENT(3A)(ALGORITH? OR ALLOCAT? OR SELECT?)
- L15 CARCINOMA, HEPATOCELLULAR+AUTO/CT(L)TH/CT
- L16 L10 AND (L11-L15)
- L17 (HEPATOCELL? OR HAEPATOCELL? OR HCC OR HCCS)/TI AND L16

【第3章 予防】

CQ17: B型慢性肝疾患からの肝発癌予防として推奨できる治療法は何か? [PubMed]

#1 "Liver Neoplasms"[MH] AND ("lamivudine"[MH] OR "lamivudine"[tiab] OR "adefovir dipivoxil" [Supplementary Concept] OR adefovir[tiab] OR "tenofovir disoproxil" [MH] OR tenofovir [tiab] OR "entecavir" [Supplementary Concept] OR entecavir[tiab] OR 3TC[tiab] OR emtricitabine [Supplementary Concept] OR emtricitabine[tiab]) AND 2012/1/1:2016/06/30[DP] AND Eng[la] AND hasabstract[text] NOT "case reports"[pt]

CQ18: C型慢性肝疾患からの肝発癌予防として推奨できる治療法は何か? [PubMed]

#1 "Liver Neoplasms"[MH] AND "Antiviral Agents"[MH] AND 2012/1/1:2016/6/30[dp] AND Eng[la] AND hasabstract[text] NOT "case reports"[pt]

CQ19: ウイルス性・非ウイルス性を問わず慢性肝疾患からの肝発癌予防法として推奨できるのは何か? [PubMed]

#1 "Carcinoma, Hepatocellular/prevention and control"[MH] AND 2012/1/1:2016/6/30[dp] AND Eng[la] AND hasabstract[text] NOT "case reports"[pt]

【第4章 手術】

CQ20: 肝切除はどのような患者に行うのが適切か? [MEDLINE]

L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT

L2 L1/HUMAN or (L1 NOT ANIMALS)

L3 L2/ENG

L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS

L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI

L6 L4 NOT L5

L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT

L8 L4 and L7

L9 L6 or L8

L10 HEPATECTOMY+NT/CT

L11 LIVER NEOPLASMS+NT/CT(L)SU/CT

L12 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

L13 (INDICAT? or ADAPT? or RECOMMEND? or SELECT? or CHOIC? or TARGET?)(3A)(PATIENT or PATIENTS or SUBJECT or SUBJECTS or CASE or CASES)

L14 (EFFECTIV? or BENEFIT?)(3A)(PATIENT or PATIENTS or SUBJECT or SUBJECTS or CASE or CASES)

L15 INDICAT?/TI or INDICAT?(3A)(SURGER? or SURGIC? or RESECT? or OPERAT? or HEPATECTOM?)

L16 L9 and (L10 or L11 or L12) and (L13 or L14 or L15)

CQ21: 肝切除前肝機能の適切な評価法は? [MEDLINE]

L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or

HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT

L2 L1/HUMAN or (L1 NOT ANIMALS)

L3 L2/ENG

L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS

L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI

L6 L4 NOT L5

L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT

L8 L4 and L7

L9 L6 or L8

L10 (HCC or LIVER or HEPAT? or NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)(3A)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)

L11 HEPATECTOM?

L12 L9 AND (L10 OR L11)

L13 PREOPERAT? or PRESURGER? or (BEFORE or PRE or PRIOR)(W)(OPERAT? or SURGER?)

L14 PREDICT?/CT AND SURGERY/CT

L15 L13 or L14

L16 L15(3A)(ASSESSMENT? OR TEST#)

L17 L15 AND (HEPAT? OR LIVER)(3A)(FUNCTION? OR STATUS?)

L18 L12 AND (L16 OR L17)

CQ22 : 安全で合理的な手術術式とは ? [MEDLINE]

L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL# or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT

L2 L1/HUMAN or (L1 NOT ANIMALS)

L3 L2/ENG

L4 L3 AND PY=>2011 AND UP=20120101-20160630 not epub?/fs

L5 LIVER NEOPLASMS+NT/CT(L)SU/CT

L6 HEPATECTOMY+NT/CT

L7 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

L8 (NEW? OR STANDARD? OR GOLDSTANDARD? OR APPROACH? OR METHOD? OR TECHNI?)/TI

L9 HEPATECTOMY+NT/CT(L)METHODS/CT

L10 (L5 or L6) and L7 and L8

L11 (SEGMENT? OR SUBSEGMENT?)/TI and (L5 or L6) and L8

L12 L4 and (L9 or L10 or L11)

L13 (ANATOMI? or SYSTEMIC? or SYSTEMATIC?)(4A)(RESECT? or HEPATECTOM? or SURGER? or SURGICA? or OPERATI?)

L14 PROGNOSIS+NT/CT or PROGNOS? or CONSEQUENCE? or OUTCOME? or SURVIVAL? or RECURRENCE? or RELAPSE? or REOCCURRENCE?

L15 L4 and L13 and L14

L16 L12 or L15

CQ23 : 腹腔鏡下肝切除術の手術適応は ? [MEDLINE]

L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI

L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS

L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)

L4 L3 AND EN/LA

L5 HEPATECTOM? OR (LIVER OR HEPATIC)(3A)(RESECT? OR EXCISION?) OR LIVER NEOPLASMS+NT/CT(L)SU/CT

L6 LAPAROSCOPY+NT/CT OR LAPAROSCOPI?

L7 PNEUMOPERITONE? OR OUTCOME? OR RECURREN? OR RELAPSE? OR INDICAT?

L8 L4 AND L5 AND L6 AND L7

L9 LAPAROSCOPI?/TI AND L8

CQ24 : 肝切除後の予後因子は何か ? [MEDLINE]

L1 QUE (GUIDELINE or PRACTICE GUIDELINE or CONSENSUS DEVELOPMENT CONFERENCE?)/DT or (GUIDELINES or PRACTICE GUIDELINES?)/CT or RECOMMENDATION?/TI or GUIDELINE?/TI or CLINICAL PROTOCOLS/CT or PATIENT CARE PLANNING+NT/CT or EVIDENCE-BASED MEDICINE+NT/CT

L2 QUE (CLINICAL or CRITICAL)(1W)(PATH or PATHS or PATHWAY?)/TI or (CLINICAL or TREATMENT?)(2A)PROTOCOL?/TI or CARE(1A)PLANNING?/TI or (GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

L3 QUE (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI or PEER REVIEW+NT/CT or (COCHRANE DATABASE SYST REV or ACP JOURNAL CLUB or ACP J CLUB or HEALTH TECHNOL ASSESS or EVID REP TECHNOL ASSESS?)/JT

L4 QUE META-ANALYSIS/DT or META-ANALYSIS/CT or (META()ANALY? or METAANAL?)/TI

L5 QUE RANDOMIZED CONTROLLED TRIAL/DT or RANDOMIZED CONTROLLED TRIALS?/CT or RANDOM ALLOCATION/CT or RANDOM? or DOUBLE-BLIND METHOD/CT or SINGLE-BLIND METHOD/CT or (SINGL? or DOUBLE? or TREBL? or TRIPL?)(W)(BLIND? or MASK?)

L6 QUE CONTROLLED CLINICAL TRIAL/DT or CONTROLLED CLINICAL TRIALS AS TOPIC+NT/CT or PLACEBOS/CT or SINGLE-BLIND METHOD/CT or CROSS-OVER STUDIES/CT or PLACEBO? or COMPARATIVE STUDY/DT or COMPARATIVE STUDY/CT or CONTROL?(1W)(TRIAL? or STUD?)

L7 QUE CLINICAL STUDY/DT or CLINICAL TRIAL?/DT or CLINICAL TRIALS AS TOPIC+NT/CT or (PHASE or CLINICAL or PILOT or ESCALAT? or DOSE)(2W)(TRIAL? or STUDY or STUDIES)/TI

L8 QUE COHORT STUDIES+NT/CT or (RETROSPECTIV? or PROSPECTIV? or LONGITUDIN? or

CROSS()SECTION? or COHORT? or FOLLOW()UP or FOLLOWUP)(1W)(STUDY or STUDIES)/TI or EPIDEMIOLOGIC STUDIES+NT/CT

- L9 QUE MULTICENTER STUDY/DT or MULTICENTER STUDIES/CT or (MULTICENT? or MULTI(W)CENT?)/TI
- L10 QUE CASE-CONTROL STUDIES+NT/CT or MATCHED-PAIR ANALYSIS/CT or CASE()CONTROL/TI
- L11 QUE L1-L10
- L12 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L13 L12/HUMAN or (L12 NOT ANIMALS)
- L14 L13/ENG
- L15 L14 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L16 L11 and L15
- L17 (HCC or LIVER or HEPAT?)(3A)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
- L18 HEPATECTOM?
- L19 L16 AND (L17 OR L18)
- L20 (PREDICT? OR PROGNOS?)(A)(FACTOR? OR VARIABL?)
- L21 L19 AND L20
- L22 L21 AND *CARCINOMA, HEPATOCELLULAR+NT/CT

CQ25 : 切除断端距離は予後に寄与するか ? [MEDLINE]

- L1 QUE (GUIDELINE or PRACTICE GUIDELINE or CONSENSUS DEVELOPMENT CONFERENCE?)/DT or (GUIDELINES or PRACTICE GUIDELINES?)/CT or RECOMMENDATION?/TI or GUIDELINE?/TI or CLINICAL PROTOCOLS/CT or PATIENT CARE PLANNING+NT/CT or EVIDENCE-BASED MEDICINE+NT/CT
- L2 QUE (CLINICAL or CRITICAL)(1W)(PATH or PATHS or PATHWAY?)/TI or (CLINICAL or TREATMENT?)(2A)PROTOCOL?/TI or CARE(1A)PLANNING?/TI or (GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
- L3 QUE (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI or PEER REVIEW+NT/CT or (COCHRANE DATABASE SYST REV or ACP JOURNAL CLUB or ACP J CLUB or HEALTH TECHNOL ASSESS or EVID REP TECHNOL ASSESS?)/JT
- L4 QUE META-ANALYSIS/DT or META-ANALYSIS/CT or (META()ANALY? or METAANAL?)/TI
- L5 QUE RANDOMIZED CONTROLLED TRIAL/DT or RANDOMIZED CONTROLLED TRIALS?/CT or RANDOM ALLOCATION/CT or RANDOM? or DOUBLE-BLIND METHOD/CT or SINGLE-BLIND METHOD/CT or (SINGL? or DOUBLE? or TREBL? or TRIPL?)(W)(BLIND? or MASK?)
- L6 QUE CONTROLLED CLINICAL TRIAL/DT or CONTROLLED CLINICAL TRIALS AS TOPIC+NT/CT or PLACEBOS/CT or SINGLE-BLIND METHOD/CT or CROSS-OVER STUDIES/CT or PLACEBO? or COMPARATIVE STUDY/DT or COMPARATIVE STUDY/CT or CONTROL?(1W)(TRIAL? or STUD?)
- L7 QUE CLINICAL STUDY/DT or CLINICAL TRIAL?/DT or CLINICAL TRIALS AS TOPIC+NT/CT or (PHASE

- or CLINICAL or PILOT or ESCALAT? or DOSE)(2W)(TRIAL? or STUDY or STUDIES)/TI
- L8 QUE COHORT STUDIES+NT/CT or (RETROSPECTIV? or PROSPECTIV? or LONGITUDIN? or CROSS()SECTION? or COHORT? or FOLLOW()UP or FOLLOWUP)(1W)(STUDY or STUDIES)/TI or EPIDEMIOLOGIC STUDIES+NT/CT
- L9 QUE MULTICENTER STUDY/DT or MULTICENTER STUDIES/CT or (MULTICENT? or MULTI(W)CENT?)/TI
- L10 QUE CASE-CONTROL STUDIES+NT/CT or MATCHED-PAIR ANALYSIS/CT or CASE()CONTROL/TI
- L11 QUE L1-L10
- L12 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L13 L12/HUMAN or (L12 NOT ANIMALS)
- L14 L13/ENG
- L15 L14 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L16 L11 and L15
- L17 (HCC or LIVER or HEPAT?)(3A)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
- L18 HEPATECTOM?
- L19 L16 AND (L17 OR L18)
- L20 SPECIM? OR SAMPL? OR TISSUE OR ORGANIZATION? OR MARGIN?
- L21 QUE PROGNOSIS+NT/CT or PROGNOS? or (TREATMENT? or LATE? or LONG(1W)TERM)(2A)(CONSEQUENCE? or OUTCOME? or RESULT?) or SURVIVAL(1W)RATE? or RECURRENCE? or RELAPSE? or REOCCURRENCE?
- L22 L19 AND L20 AND L21
- L23 L22 AND *CARCINOMA, HEPATOCELLULAR+NT/CT
- CQ26 : 肝流入血流遮断や中心静脈圧低下は，肝切離中出血量を減少させるか？ [MEDLINE]
- L1 QUE (GUIDELINE or PRACTICE GUIDELINE or CONSENSUS DEVELOPMENT CONFERENCE?)/DT or (GUIDELINES or PRACTICE GUIDELINES?)/CT or RECOMMENDATION?/TI or GUIDELINE?/TI or CLINICAL PROTOCOLS/CT or PATIENT CARE PLANNING+NT/CT or EVIDENCE-BASED MEDICINE+NT/CT
- L2 QUE (CLINICAL or CRITICAL)(1W)(PATH or PATHS or PATHWAY?)/TI or (CLINICAL or TREATMENT?)(2A)PROTOCOL?/TI or CARE(1A)PLANNING?/TI or (GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
- L3 QUE (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI or PEER REVIEW+NT/CT or (COCHRANE DATABASE SYST REV or ACP JOURNAL CLUB or ACP J CLUB or HEALTH TECHNOL ASSESS or EVID REP TECHNOL ASSESS?)/JT
- L4 QUE META-ANALYSIS/DT or META-ANALYSIS/CT or (META()ANALY? or METAANAL?)/TI
- L5 QUE RANDOMIZED CONTROLLED TRIAL/DT or RANDOMIZED CONTROLLED TRIALS?/CT or RANDOM ALLOCATION/CT or RANDOM? or DOUBLE-BLIND METHOD/CT or SINGLE-BLIND METHOD/CT or

(SINGL? or DOUBLE? or TREBL? or TRIPL?)(W)(BLIND? or MASK?)

- L6 QUE CONTROLLED CLINICAL TRIAL/DT or CONTROLLED CLINICAL TRIALS AS TOPIC+NT/CT or PLACEBOS/CT or SINGLE-BLIND METHOD/CT or CROSS-OVER STUDIES/CT or PLACEBO? or COMPARATIVE STUDY/DT or COMPARATIVE STUDY/CT or CONTROL?(1W)(TRIAL? or STUD?)
- L7 QUE CLINICAL STUDY/DT or CLINICAL TRIAL?/DT or CLINICAL TRIALS AS TOPIC+NT/CT or (PHASE or CLINICAL or PILOT or ESCALAT? or DOSE)(2W)(TRIAL? or STUDY or STUDIES)/TI
- L8 QUE COHORT STUDIES+NT/CT or (RETROSPECTIV? or PROSPECTIV? or LONGITUDIN? or CROSS()SECTION? or COHORT? or FOLLOW()UP or FOLLOWUP)(1W)(STUDY or STUDIES)/TI or EPIDEMIOLOGIC STUDIES+NT/CT
- L9 QUE MULTICENTER STUDY/DT or MULTICENTER STUDIES/CT or (MULTICENT? or MULTI(W)CENT?)/TI
- L10 QUE CASE-CONTROL STUDIES+NT/CT or MATCHED-PAIR ANALYSIS/CT or CASE()CONTROL/TI
- L11 QUE L1-L10
- L12 L11 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS
- L13 (L12/HUMAN OR (L12 NOT ANIMALS)) AND ENGLISH/LA
- L14 SU/CT OR SURGERY+NT/CT OR SURGICAL PROCEDURES, OPERATIVE+NT/CT OR SURGER### OR OPERAT? OR HEPATECTOMY+NT/CT OR HEPATECTOM? OR (TUMOR? OR TUMOUR? OR CANCER? OR CARCINOM? OR LIVER? OR HEPAT?)(3A)(RESECT? OR REMOV? OR ENUCLEAT? OR EXTIRPAT? OR EXCIS? OR AMPUTAT? OR ABLAT?)
- L15 BLOOD LOSS, SURGICAL+NT/CT OR BLOOD(W)LOSS? OR (HEMORRHAGE? OR BLEED? OR HAEMORRHAG?)(3A)(OP OR SURGIC? OR SURGER### OR OPERAT? OR HEPATECTOM? OR RESECT? OR REMOV? OR ENUCLEAT? OR EXTIRPAT? OR EXCIS? OR AMPUTAT? OR ABLAT?)
- L16 L13 AND L14 AND L15
- L17 ((CENTRAL?(1W)VENOUS?(1W)PRESSUR?) OR CVP)(3A)(REDUC? OR LOW OR DECREAS? OR FALL## OR DROP###)
- L18 PEDICL?(1W)(CLAMP? OR OCCLUS?) OR IPO OR HPC OR PRINGL? OR PORTAL(W)TRIAD(W)CLAMP? OR PTC
- L19 S L16 AND (L17 OR L18)

CQ27 : 肝切除において腹腔ドレーン留置は必要か？ [MEDLINE]

- L1 QUE (GUIDELINE or PRACTICE GUIDELINE or CONSENSUS DEVELOPMENT CONFERENCE?)/DT or (GUIDELINES or PRACTICE GUIDELINES?)/CT or RECOMMENDATION?/TI or GUIDELINE?/TI or CLINICAL PROTOCOLS/CT or PATIENT CARE PLANNING+NT/CT or EVIDENCE-BASED MEDICINE+NT/CT
- L2 QUE (CLINICAL or CRITICAL)(1W)(PATH or PATHS or PATHWAY?)/TI or (CLINICAL or TREATMENT?)(2A)PROTOCOL?/TI or CARE(1A)PLANNING?/TI or (GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
- L3 QUE (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI or PEER REVIEW+NT/CT or (COCHRANE DATABASE SYST REV or ACP JOURNAL CLUB or ACP J CLUB or HEALTH TECHNOL ASSESS or EVID REP TECHNOL ASSESS?)/JT
- L4 QUE META-ANALYSIS/DT or META-ANALYSIS/CT or (META()ANALY? or METAANAL?)/TI

- L5 QUE RANDOMIZED CONTROLLED TRIAL/DT or RANDOMIZED CONTROLLED TRIALS?/CT or RANDOM ALLOCATION/CT or RANDOM? or DOUBLE-BLIND METHOD/CT or SINGLE-BLIND METHOD/CT or (SINGL? or DOUBLE? or TREBL? or TRIPL?)(W)(BLIND? or MASK?)
- L6 QUE CONTROLLED CLINICAL TRIAL/DT or CONTROLLED CLINICAL TRIALS AS TOPIC+NT/CT or PLACEBOS/CT or SINGLE-BLIND METHOD/CT or CROSS-OVER STUDIES/CT or PLACEBO? or COMPARATIVE STUDY/DT or COMPARATIVE STUDY/CT or CONTROL?(1W)(TRIAL? or STUD?)
- L7 QUE CLINICAL STUDY/DT or CLINICAL TRIAL?/DT or CLINICAL TRIALS AS TOPIC+NT/CT or (PHASE or CLINICAL or PILOT or ESCALAT? or DOSE)(2W)(TRIAL? or STUDY or STUDIES)/TI
- L8 QUE COHORT STUDIES+NT/CT or (RETROSPECTIV? or PROSPECTIV? or LONGITUDIN? or CROSS()SECTION? or COHORT? or FOLLOW()UP or FOLLOWUP)(1W)(STUDY or STUDIES)/TI or EPIDEMIOLOGIC STUDIES+NT/CT
- L9 QUE MULTICENTER STUDY/DT or MULTICENTER STUDIES/CT or (MULTICENT? or MULTI(W)CENT?)/TI
- L10 QUE CASE-CONTROL STUDIES+NT/CT or MATCHED-PAIR ANALYSIS/CT or CASE()CONTROL/TI
- L11 QUE L1-L10
- L12 L11 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS
- L13 (L12/HUMAN OR (L12 NOT ANIMALS)) AND ENGLISH/LA
- L14 SU/CT OR SURGERY+NT/CT OR SURGICAL PROCEDURES, OPERATIVE+NT/CT OR SURGER### OR OPERAT? OR HEPATECTOMY+NT/CT OR HEPATECTOM? OR (TUMOR? OR TUMOUR? OR CANCER? OR CARCINOM? OR LIVER? OR HEPAT?)(3A)(RESECT? OR REMOV? OR ENUCLEAT? OR EXTIRPAT? OR EXCIS? OR AMPUTAT? OR ABLAT?)
- L15 ABDOM?(2A)DRAIN?
- L16 L13 AND L14 AND L15

CQ28 : 肝切除前に補助療法を行うか？ [MEDLINE]

- L1 QUE (GUIDELINE or PRACTICE GUIDELINE or CONSENSUS DEVELOPMENT CONFERENCE?)/DT or (GUIDELINES or PRACTICE GUIDELINES?)/CT or RECOMMENDATION?/TI or GUIDELINE?/TI or CLINICAL PROTOCOLS/CT or PATIENT CARE PLANNING+NT/CT or EVIDENCE-BASED MEDICINE+NT/CT
- L2 QUE (CLINICAL or CRITICAL)(1W)(PATH or PATHS or PATHWAY?)/TI or (CLINICAL or TREATMENT?)(2A)PROTOCOL?/TI or CARE(1A)PLANNING?/TI or (GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
- L3 QUE (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI or PEER REVIEW+NT/CT or (COCHRANE DATABASE SYST REV or ACP JOURNAL CLUB or ACP J CLUB or HEALTH TECHNOL ASSESS or EVID REP TECHNOL ASSESS?)/JT
- L4 QUE META-ANALYSIS/DT or META-ANALYSIS/CT or (META()ANALY? or METAANAL?)/TI
- L5 QUE RANDOMIZED CONTROLLED TRIAL/DT or RANDOMIZED CONTROLLED TRIALS?/CT or RANDOM ALLOCATION/CT or RANDOM? or DOUBLE-BLIND METHOD/CT or SINGLE-BLIND METHOD/CT or (SINGL? or DOUBLE? or TREBL? or TRIPL?)(W)(BLIND? or MASK?)
- L6 QUE CONTROLLED CLINICAL TRIAL/DT or CONTROLLED CLINICAL TRIALS AS TOPIC+NT/CT or PLACEBOS/CT or SINGLE-BLIND METHOD/CT or CROSS-OVER STUDIES/CT or PLACEBO? or

- COMPARATIVE STUDY/DT or COMPARATIVE STUDY/CT or CONTROL?(1W)(TRIAL? or STUD?)
- L7 QUE CLINICAL STUDY/DT or CLINICAL TRIAL?/DT or CLINICAL TRIALS AS TOPIC+NT/CT or (PHASE or CLINICAL or PILOT or ESCALAT? or DOSE)(2W)(TRIAL? or STUDY or STUDIES)/TI
- L8 QUE COHORT STUDIES+NT/CT or (RETROSPECTIV? or PROSPECTIV? or LONGITUDIN? or CROSS()SECTION? or COHORT? or FOLLOW()UP or FOLLOWUP)(1W)(STUDY or STUDIES)/TI or EPIDEMIOLOGIC STUDIES+NT/CT
- L9 QUE MULTICENTER STUDY/DT or MULTICENTER STUDIES/CT or (MULTICENT? or MULTI(W)CENT?)/TI
- L10 QUE CASE-CONTROL STUDIES+NT/CT or MATCHED-PAIR ANALYSIS/CT or CASE()CONTROL/TI
- L11 QUE L1-L10
- L12 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L13 L12/HUMAN or (L12 NOT ANIMALS)
- L14 L13/ENG
- L15 L14 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L16 L11 and L15
- L17 SU/CT or SURGERY+NT/CT or SURGICAL PROCEDURES, OPERATIVE+NT/CT or SURGER### or OPERAT? or HEPATECTOMY+NT/CT or HEPATECTOM? or POSTOPERAT? or POSTSURGER? or POSTHEPATECTOM?
- L18 (TUMOR? or TUMOUR? or CANCER? or CARCINOM? or LIVER? or HEPAT?)(3A)(RESECT? or REMOV? or ENUCLEAT? or EXTIRPAT? or EXCIS? or AMPUTAT? or ABLAT?)
- L19 NEOADJUVANT? or NAC or NEO()ADJUVAN?
- L20 (PREOPERAT? or (BEFORE or PRE)(3A)(SURGER### or OPEARAT? or HEPATECTOM? or RESECT?))(4A)(CHEMOEMB? or EMBOL? or CHEMOTHER? or THERAP? or TREAT? or ADMINIST?)
- L21 (ANTINEOPLASTIC AGENTS+NT/CT OR DT/CT or CHEMOTHERAP? or DRUG THERAPY+NT/CT) and (PREOPERAT? or (BEFORE or PRE)(3A)(SURGER### or OPEARAT? or HEPATECTOM? or RESECT?))
- L22 L16 and (L17 or L18) and (L19 or L20 or L21)
- L23 QUE PROGNOSIS+NT/CT or PROGNOS? or CONSEQUENCE? or OUTCOME? or SURVIVAL? or RECURRENCE? or RELAPSE? or REOCCURRENCE?
- L24 L22 and L23

CQ29 : 肝細胞癌に対する肝移植の適応基準は何か？ [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA#)/TI OR (HCC OR HCCS)/TI AND LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN OR (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE(W)REPORT?/TI

- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 AND L7
- L9 L6 OR L8
- L10 LIVER TRANSPLANTATION+NT/CT(L)UT/CT OR TRANSPLANT?(3A)UTILIZ?
- L11 (INDICAT? OR ADAPT? OR RECOMMEND? OR SELECT? OR CHOIC? OR TARGET? OR ELIGIBL? OR CANDIDAT? OR OFFER?)(4A)TRANSPLANT?
- L12 CRITERI?(4A)L11
- L13 L9 AND L10
- L14 L9 AND L12
- L15 L9 AND L11
- L16 L9 AND TRANSPLAN?/TI AND (CRITERI? OR PRIORIT?)
- L17 L13 OR L14 OR L15 OR L16

CQ30 : 肝移植前のダウンスレージングは肝移植の予後を改善するか？ [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN or (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 LIVER TRANSPLANTATION+NT/CT OR LIVER+NT/CT(L)TR/CT OR TRANSPLAN?
- L11 DOWN?()STAG? OR DOWNSTAG?
- L12 L9 and L10 and L11
- L13 PRE()TRANSPLAN? OR PRETRANSPLAN? OR TRANSPLAN?(3A)(BEFOR? OR FOLLO? OR AFTER? OR WAIT?)
- L14 BRIDGING? OR ABLAT? OR RFA
- L15 (LOCAL? or LOCOREGION? or LOCO()REGION? or TOPICAL? OR BRIDG?)(3A)(THERAP? or TREAT?)
- L16 TAE OR TACE OR (TRANSCATHETER? OR TRANSARTER?)(3A)(EMBOLI? OR CHEMOEMBOLI?)
- L17 L13(5A)(L14 or L15 or L16)
- L18 L9 and L17
- L19 L12 or L18

【第5章 穿刺局所療法】

CQ31 : 穿刺局所療法はどのような患者に行うのが適切か？ [PubMed]

CQ32 : 各穿刺局所療法の選択は、どのように行うのが適切か？ [PubMed]

#1 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2007/7/1:2011/12/31[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#2 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#3 #1 AND #2

CQ33 : 穿刺局所療法に TACE を併用することで予後を改善できるか？ [PubMed]

#1 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2007/7/1:2011/12/31[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#2 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#3 ("TACE"[tiab] OR "TAE"[tiab] OR "transarterial"[tiab] OR "transcatheter"[tiab])

#4 #1 AND #2 AND #3

CQ34 : 造影超音波や fusion imaging は局所療法の治療ガイドとして有用か？ [PubMed]

#1 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2007/7/1:2011/12/31[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#2 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR

"radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab] AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#3 ("fusion"[tiab])

#4 (sonazoid[TIAB] OR "contrast-enhanced ultrasonography"[TIAB] OR "contrast-enhanced ultrasound"[TIAB] OR "CEUS"[TIAB])

#5 #1 AND #2 AND #3 AND #4

CQ35 : 穿刺局所療法の効果判定に有用な画像診断は何か？ [PubMed]

#1 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 1982/1/1:2011/12/31[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#2 ("Carcinoma, hepatocellular"[MH] OR "hepatocellular"[tiab] OR "HCC"[tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA"[tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND (comparison[tiab] OR compare[tiab] OR compared[tiab] OR "versus"[tiab] OR "vs"[tiab]) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

#3 ("MRI"[tiab] OR "CT"[tiab] OR ultrasonography[tiab] OR ultrasound[tiab] OR ultrasonographic[tiab]

#4 "survival analysis"[MH]

#5 #1 AND #2 AND #3 AND #4

CQ36 : 穿刺局所療法の効果判定に有用な画像診断は何か？ [PubMed]

#1 ("carcinoma, hepatocellular"[MH] OR "hepatocellular" [tiab] OR "HCC" [tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency"[tiab] OR "RFA"[tiab] OR "RFTA" [tiab] OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND ("risk factors"[MH] OR "survival analysis"[MH]) AND 2006/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

【第6章 肝動脈(化学) 塞栓療法 TA(C) E】

CQ37 : TACE/TAE ほどのような患者に行うのが適切か？ [MEDLINE]

L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT

L2 L1/HUMAN or (L1 NOT ANIMALS)

L3 L2/ENG

L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS

- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 (ANTITHROMBOTIC or ANTI(1W)THROMBOTIC)(1W)REGIMEN? or EMBOLIZE? or (EMBOL? or THROMBUS?)(1A)FORM? or EMBOLIZATION, THERAPEUTIC+NT/CT or TAE or TACE or ((TRANSCATHETER? or TRANSARTER? or TRANSARTERIAL? or TRANS)(W)(CATHETER? or ARTER### or ARTERIAL?))(3A)(EMBOLI? or CHEMOEMBOLI?)
- L11 (INDICAT? or ADAPT? or RECOMMEND? or SELECT? or CHOIC? or TARGET?)(3A)(PATIENT or PATIENTS or SUBJECT or SUBJECTS or CASE or CASES)
- L12 (EFFECTIV? or BENEFIT?)(3A)(PATIENT or PATIENTS or SUBJECT or SUBJECTS or CASE or CASES)
- L13 INDICAT?/TI or INDICAT?(3A)(ETHANOL? or RFA or PEI or PMCT or ABLAT?)
- L14 L9 and L10 and (L11-L13)

CQ38 : TACE/TAE において塞栓物質や抗癌剤の選択はどのように行うのが適切か？ [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN or (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 (ANTITHROMBOTIC or ANTI(1W)THROMBOTIC)(1W)REGIMEN? or TAE or TACE
- L11 ((TRANSCATHETER? or TRANSARTER? or TRANSARTERIAL? or TRANS)(W)(CATHETER? or ARTER### or ARTERIAL?))(3A)(EMBOLI? or CHEMOEMBOLI? or INFUS? OR INJECT? OR CHEMOINFU?)
- L12 CHEMOEMBOLIZATION, THERAPEUTIC+NT/CT
- L13 L9 and (L10 or L11 or L12)
- L14 QUE AD/CT or TU/CT
- L15 ANTINEOPLASTIC AGENTS+NT/CT(L)(TU or AD)/CT
- L16 L13 and (L14 or L15)
- L17 TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI?

- L18 QUE SUSPENS? OR MICROSPHE? OR OIL# OR CARRIER? OR BEAD# OR MATERIAL? OR AGENT# OR DRUG# OR COMPOUND# OR EMULS?
- L19 L9 and L17/TI and L18/TI
- L20 L17/TI and L16
- L21 L20 and L18/CT
- L22 L19 or L21

CQ39 : 再塞栓療法の時期を決定する因子は何か? [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN or (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 (ANTITHROMBOTIC or ANTI(1W)THROMBOTIC)(1W)REGIMEN? or TAE or TACE
- L11 ((TRANSCATHETER? or TRANSARTER? or TRANSARTERIAL? or TRANS)(W)(CATHETER? or ARTER### or ARTERIAL?))(3A)(EMBOLI? or CHEMOEMBOLI? or INFUS? OR INJECT? OR CHEMOINFU?)
- L12 CHEMOEMBOLIZATION, THERAPEUTIC+NT/CT OR CHEMOTHERAPY, ADJUVANT+NT/CT
- L13 L9 and (L10 or L11 or L12)
- L14 RETRI? or RE()TRI### or RETRY? or RE()TRY? or TRY()AGAIN? or REPERFORM? or RE()PERFORM?
- L15 QUE ANOTHER? or REPEAT? or ADDITION? or SUPPLEMENT? or TWICE? or TWO()TIMES? or RETREATMENT? or RE()TREATMENT? or AGAIN?
- L16 QUE SECOND? OR 2ND
- L17 RETHERAP? OR REAPPROACH? OR RE()(THERAP? OR APPROACH?)
- L18 REEMBOLI? OR RECHEMOEMBOLI? OR RETRANSCATHE? OR RETRANSARTER?
- L19 L13 and (L14/TI or L15/TI or L16/TI or L17/TI or L18/TI)
- L20 QUE TIME? OR TIMING? OR PERIOD? OR INTERVAL? OR OCCASION? OR POINT?
- L21 L13 and (L14 or L15 or L16 or L17 or L18)
- L22 L21 and L20
- L23 (L14 or L15 or L16 or L17)(4A)(TACE OR TAE OR TRANSCATHE? OR TRANSARTE? OR EMBOLI? OR CHEMOEMBOLI? OR TREAT? OR THERAP?)
- L24 L23 and L21
- L25 TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI? OR TAE OR TACE

L26 (L24 or L22) and L25/TI

L27 L26 or L19

CQ40 : TACE の効果判定に有用な画像診断は何か? [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL# OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA#)/TI OR (HCC OR HCCS)/TI AND LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN OR (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS
- L5 ULTRASONOGRAPHY+NT/CT OR ULTRASON? OR ECHOGRAPH? OR ECHO# OR SONOGR? OR ULTRASOUND? OR ULTRASONICS+NT/CT OR US/CT
- L6 (ANTITHROMBOTIC OR ANTI(1W)THROMBOTIC)(1W)REGIMEN? OR EMBOLIZE? OR (EMBOL? OR THROMBUS?)(1A)FORM? OR EMBOLIZATION, THERAPEUTIC+NT/CT OR TAE OR TACE OR ((TRANSCATHETER? OR TRANSARTER? OR TRANS)(W)(CATHETER? OR ARTER###))(3A)(EMBOLI? OR CHEMOEMBOLI? OR INFUS? OR INJECT? OR CHEMOINFU?)
- L7 (LOCAL OR TOPICAL)(3A)(REMEDI? OR THERAP? OR TREATMENT?)
- L8 L4 AND L5 AND (L6 OR L7)
- L9 L4 AND L6
- L10 ((ANTITHROMBOTIC OR ANTI(1W)THROMBOTIC)(1W)REGIMEN? OR TAE OR TACE OR CHEMOEMBOLI? OR CHEMOINFU? OR LOCOREGIONAL?(W)THERAP?)/TI
- L11 RA/CT OR US/CT OR RI/CT OR DIAGNOSTIC IMAGING+NT/CT OR LIVER NEOPLASMS+NT/CT(L)PA/CT
- L12 ((TUMOR OR TUMOUR)(W)RESPONSE? OR INDICATOR? OR VISUALIZ? OR ASSESS? OR EVALUAT? OR THERAPEUTIC(W)EFFECT? OR IMAGING? OR FEATURE? OR FINDING? OR CT OR MR OR MRI)/TI
- L13 (USEFUL? OR EFFECTIVE? OR EFFICAC? OR BENEFIT?)/TI
- L14 L9 AND L10 AND L11
- L15 L14 AND (L12 OR L13)
- L16 L8 OR L15

CQ41 : 塞栓療法と分子標的治療薬を併用するのは適切か? [MEDLINE]

- L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS
- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 *CHEMOEMBOLIZATION, THERAPEUTIC+AUTO/CT(L)METHODS
- L6 TACE OR TAE OR (TRANSARTER? OR TRANSCATHETER? OR (TRANS OR TRANSCATHETER?)(W)ARTERI?)(2W)(CHEMOEMBOLI? OR EMBOLI?)
- L7 *CARCINOMA, HEPATOCELLULAR+AUTO/CT(L)TH/CT
- L8 SORAFENIB? OR MOLECUL?(2A)TARGET? OR (MULTIKINASE? OR KINASE?)(2A)INHIBITOR?

- L9 *ANTINEOPLASTIC AGENTS+AUTO/CT(L)TU/CT
- L10 ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS+AUTO/CT
- L11 COMBINED MODALITY THERAPY+AUTO/CT
- L12 DRUG THERAPY, COMBINATION+AUTO/CT
- L13 L4 AND (L5 OR L6) AND L7 AND (L8 OR L9) AND (L10 OR L11 OR L12)
- L14 L4 AND (TACE/TI OR TAE/TI OR (TRANSARTER?/TI OR TRANSCATHETER?/TI OR (TRANS/TI OR TRANSCATHETER?/TI)(W)ARTERI?/TI)(2W)(CHEMOEMBOLI?/TI OR EMBOLI?/TI)) AND (SORAFENIB?/TI OR MOLECUL?/TI(2A)TARGET?/TI OR (MULTIKINASE?/TI OR KINASE?/TI)(2A)INHIBITOR?/TI)
- L15 L13 OR L14

CQ42 : どのような場合に TACE 不応と考えるか ? [MEDLINE]

- L1 LIVER NEOPLASMS+NT/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA# OR HCC OR HCCS)/TI
- L2 L1 AND 1982-2016/PY AND 19820101-20160630/UP NOT EPUB?/FS
- L3 L2/HUMAN OR L2 NOT (ANIMALS+NT/CT)
- L4 L3 AND EN/LA
- L5 CHEMOEMBOLIZATION, THERAPEUTIC+AUTO/CT
- L6 TACE OR TAE OR CHEMOEMBOLI? OR EMBOLI?
- L7 L4 AND (L5 OR L6)
- L8 L6(4A)(REFRACTOR? OR FAILUR? OR RESISTAN? OR UNRESPON? OR NONRESPON? OR (UN OR NON)(W)RESPON?)
- L9 L7 AND L8

【第7章 薬物療法】

CQ43: 切除不能進行肝細胞癌に分子標的治療を行うか ? [MEDLINE]+ [PubMed]

第3版のCQ41、CQ43の検索式[MEDLINE]に加え、以下の検索式が用いられた

- #1 ((((((carcinoma, hepatocellular/drug therapy[MeSH Terms]) AND ((((((Treatment outcome) OR mortality) OR survival) OR recurrence) OR relapse))) AND "2012/1/1"[PDAT] : "2016/6/30"[PDAT]) AND (((("humans"[MeSH Terms] OR "humans"[All Fields] OR "human"[All Fields]) NOT ("animals"[MeSH Terms:noexp] OR animal[All Fields])))) AND (((("clinical trial"[Publication Type] OR "clinical trials as topic"[MeSH Terms] OR "clinical trial"[All Fields]) OR ("clinical study"[Publication Type] OR "clinical studies as topic"[MeSH Terms] OR "clinical study"[All Fields])))) NOT (("case reports"[Publication Type] OR "case report"[All Fields]))

CQ44: 切除不能進行肝細胞癌に肝動注化学療法は推奨されるか ? [MEDLINE]+ [PubMed]

第3版のCQ42の検索式[MEDLINE]に加え、以下の検索式が用いられた

#1 (((((((carcinoma, hepatocellular/drug therapy[MeSH Terms]) AND
((((((((((((intraarter*[Title/Abstract]) OR infus*[Title/Abstract]) OR inject*[Title/Abstract]))) AND
chemotherap*[Title/Abstract]))) AND (((((Treatment outcome) OR mortality) OR survival) OR
recurrence) OR relapse))) AND "2012/1/1"[PDAT] : "2016/6/30"[PDAT]) AND (((("humans"[MeSH
Terms] OR "humans"[All Fields] OR "human"[All Fields]) NOT ("animals"[MeSH Terms:noexp] OR
animal[All Fields]))) AND (((("clinical trial"[Publication Type] OR "clinical trials as topic"[MeSH
Terms] OR "clinical trial"[All Fields]) OR ("clinical study"[Publication Type] OR "clinical studies as
topic"[MeSH Terms] OR "clinical study"[All Fields]))) NOT (("case reports"[Publication Type] OR
"case report"[All Fields]))

CQ45:薬物療法の治療効果予測因子は何か？ [MEDLINE]+ [PubMed]

第3版のCQ45の検索式[MEDLINE]に加え、以下の検索式が用いられた

#1 (((((((carcinoma, hepatocellular/drug therapy[MeSH Terms]) AND (((((((((((benefit*) OR effect*) OR
effic*) OR gain*) OR performance*) OR action*) OR respon*) OR outcom*)) AND ((prognos*) OR
predict*))))) AND "2012/1/1"[PDAT] : "2016/6/30"[PDAT]) AND (((("humans"[MeSH Terms] OR
"humans"[All Fields] OR "human"[All Fields]) NOT ("animals"[MeSH Terms:noexp] OR animal[All
Fields]))) AND (((("clinical trial"[Publication Type] OR "clinical trials as topic"[MeSH Terms] OR
"clinical trial"[All Fields]) OR ("clinical study"[Publication Type] OR "clinical studies as topic"[MeSH
Terms] OR "clinical study"[All Fields]))) NOT (("case reports"[Publication Type] OR "case report"[All
Fields]))

CQ46:薬物療法の治療効果判定はどのようにするか？ [MEDLINE]+ [PubMed]

第3版のCQ46の検索式[MEDLINE]に加え、以下の検索式が用いられた

#1 (((((((carcinoma, hepatocellular/drug therapy[MeSH Terms]) AND respon*) AND "2012/1/1"[PDAT] :
"2016/6/30"[PDAT]) AND (((("humans"[MeSH Terms] OR "humans"[All Fields] OR "human"[All
Fields]) NOT ("animals"[MeSH Terms:noexp] OR animal[All Fields]))) AND (((("clinical
trial"[Publication Type] OR "clinical trials as topic"[MeSH Terms] OR "clinical trial"[All Fields]) OR
("clinical study"[Publication Type] OR "clinical studies as topic"[MeSH Terms] OR "clinical study"[All
Fields]))) NOT (("case reports"[Publication Type] OR "case report"[All Fields]))

CQ47:薬物療法の副作用とその対策は何か？ [MEDLINE]+ [PubMed]

第3版のCQ47の検索式[MEDLINE]に加え、以下の検索式が用いられた

#1 (((((((("carcinoma, hepatocellular/drug therapy"[MeSH Terms]) AND (((((((advers*) OR safety) OR

toxic*)))) AND "2012/1/1"[PDAT] : "2016/6/30"[PDAT]) AND (((("humans"[MeSH Terms] OR "humans"[All Fields] OR "human"[All Fields]) NOT ("animals"[MeSH Terms:noexp] OR animal[All Fields]))) AND (((("clinical trial"[Publication Type] OR "clinical trials as topic"[MeSH Terms] OR "clinical trial"[All Fields]) OR ("clinical study"[Publication Type] OR "clinical studies as topic"[MeSH Terms] OR "clinical study"[All Fields]))) NOT (("case reports"[Publication Type] OR "case report"[All Fields]))

【第8章 放射線療法】

CQ48 : 肝細胞癌に対する体幹部定位放射線治療は推奨されるか？ [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 STEREOTACTIC(3A)(RADIOTHERAP? OR RADIOSURG? OR RADIATION? OR IRRADIAT?)
- L3 RADIOTHERAPY+NT/CT or RT/CT or RADIOCHEM? or CHEMORADIO? or IRRADIAT? or RADIOTHERA? or RADIAT? or BRACHYTHER? or RADIOSURGE?
- L4 SBRT OR SBT OR SRT OR STEREOTACTIC OR PINPOINT?
- L5 REVIEW?/DT
- L6 L1 NOT L5
- L7 L6/HUMAN or (L6 NOT ANIMALS)
- L8 L7/ENG
- L9 L8 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L10 L9 and L2
- L11 L9 and L3 and L4
- L12 L10 or L11

CQ49 : 肝細胞癌に対する, 粒子線治療〔陽子線治療, 重粒子(炭素イオン)線治療〕は有効か？

[MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 (HEAVY OR CARBON? OR PROTON? OR PARTICL?)(2A)(THERAP? OR ION OR IONS OR BEAM OR BEAMS OR IRRADIAT? OR RADIOISOTOP?)
- L3 RADIOTHERAPY+NT/CT or RT/CT or RADIOCHEM? or CHEMORADIO? or IRRADIAT? or RADIOTHERA? or RADIAT? or BRACHYTHER? or RADIOSURGE?
- L4 REVIEW?/DT
- L5 L1 NOT L4
- L6 L5/HUMAN or (L5 NOT ANIMALS)

L7 L6/ENG
L8 L7 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
L9 L8 and L2 and L3

CQ50 : 肝細胞癌に対する, 3次元原体照射法による放射線治療はどのような場合に推奨されるか?

[MEDLINE]

L1 QUE (GUIDELINE OR PRACTICE GUIDELINE OR CONSENSUS DEVELOPMENT CONFERENCE?)/DT OR (GUIDELINES OR PRACTICE GUIDELINES?)/CT OR RECOMMENDATION?/TI OR GUIDELINE?/TI OR CLINICAL PROTOCOLS/CT OR PATIENT CARE PLANNING+NT/CT OR EVIDENCE-BASED MEDICINE+NT/CT

L2 QUE (CLINICAL OR CRITICAL)(1W)(PATH OR PATHS OR PATHWAY?)/TI OR (CLINICAL OR TREATMENT?)(2A)PROTOCOL?/TI OR CARE(1A)PLANNING?/TI OR (GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

L3 QUE (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI OR PEER REVIEW+NT/CT OR (COCHRANE DATABASE SYST REV OR ACP JOURNAL CLUB OR ACP J CLUB OR HEALTH TECHNOL ASSESS OR EVID REP TECHNOL ASSESS?)/JT

L4 QUE META-ANALYSIS/DT OR META-ANALYSIS/CT OR (META(W)ANALY? OR METAANAL?)/TI

L5 QUE RANDOMIZED CONTROLLED TRIAL/DT OR RANDOMIZED CONTROLLED TRIALS?/CT OR RANDOM ALLOCATION/CT OR RANDOM? OR DOUBLE-BLIND METHOD/CT OR SINGLE-BLIND METHOD/CT OR (SINGL? OR DOUBLE? OR TREBL? OR TRIPL?)(W)(BLIND? OR MASK?)

L6 QUE CONTROLLED CLINICAL TRIAL/DT OR CONTROLLED CLINICAL TRIALS AS TOPIC+NT/CT OR PLACEBOS/CT OR SINGLE-BLIND METHOD/CT OR CROSS-OVER STUDIES/CT OR PLACEBO? OR COMPARATIVE STUDY/DT OR COMPARATIVE STUDY/CT OR CONTROL?(1W)(TRIAL? OR STUD?)

L7 QUE CLINICAL STUDY/DT OR CLINICAL TRIAL?/DT OR CLINICAL TRIALS AS TOPIC+NT/CT OR (PHASE OR CLINICAL OR PILOT OR ESCALAT? OR DOSE)(2W)(TRIAL? OR STUDY OR STUDIES)/TI

L8 QUE COHORT STUDIES+NT/CT OR (RETROSPECTIV? OR PROSPECTIV? OR LONGITUDIN? OR CROSS(W)SECTION? OR COHORT? OR FOLLOW(W)UP OR FOLLOWUP)(1W)(STUDY OR STUDIES)/TI OR EPIDEMIOLOGIC STUDIES+NT/CT

L9 QUE MULTICENTER STUDY/DT OR MULTICENTER STUDIES/CT OR (MULTICENT? OR MULTI(W)CENT?)/TI

L10 QUE CASE-CONTROL STUDIES+NT/CT OR MATCHED-PAIR ANALYSIS/CT OR CASE(W)CONTROL/TI

L11 QUE (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)

L12 CARCINOMA, HEPATOCELLULAR/CT OR (HEPATOCELL? OR HAEPATOCELL? OR (HEPATO? OR HAEPATO? OR LIVER?)(W)(CELL## OR CELLULA?))(2A)(NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR CARCINOM?)/TI OR (HEPATOMA# OR HAEPATOMA#)/TI OR (HCC OR HCCS)/TI AND LIVER NEOPLASMS+NT/CT

L13 L11 AND L12

L14 L13/HUMAN OR (L13 NOT ANIMALS)

L15 L14/ENG

L16 L15 AND PY=>2011 AND UP=20120101-20160630 NOT EPUB?/FS

- L17 RADIO THERAPY+NT/CT OR RT/CT OR RADIOCHEM? OR CHEMORADIO? OR IRRADIAT? OR RADIO THERA? OR RADIAT? OR BRACHYTHER? OR RADIOSURGE?
- L18 L16 AND L17
- L19 QUE PROGNOSIS+NT/CT OR PROGNOS? OR OUTCOME? OR RECURRENCE? OR RELAPSE? OR REOCCURRENCE?
- L20 QUE EFFICACY OR SURVIVAL? OR RESPONSE(W)(RATE OR RATES) OR LOCAL(W)CONTROL? OR SAFETY OR ADVERS?(1W)(EFFECT? OR EVENT OR EVENTS) OR TOXICITY OR FEASIBILITY
- L21 L19 OR L20
- L22 L18 AND L21

【第9章 治療後のサーベイランス・再発予防・再発治療】

CQ51 : 肝切除後・穿刺局所療法後, どのようにフォローアップするか? [PubMed]

- #1 ("carcinoma, hepatocellular"[mh] OR "hepatocellular carcinoma"[tiab] OR "hepatoma"[tiab] OR "liver cancer"[tiab] OR HCC[tiab]) AND ("Neoplasm Recurrence, Local"[mh] OR recurrence[tiab]) AND ("surveillance"[tiab] OR "protocol"[tiab] OR "follow-up"[tiab]) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

CQ52 : 肝切除後・穿刺局所療法後の有効な再発予防法は何か? [PubMed]

- #1 ("Carcinoma, Hepatocellular/therapy"[majr] AND ("Neoplasm Recurrence, Local"[MH] OR "interferons/therapeutic use"[majr] OR "Antiviral Agents/therapeutic use"[majr])) AND 2012/1/1:2016/6/30[dp] AND hasabstract[text] AND Eng[la] NOT "case reports"[pt]

(検索対象期間 2012年1月1日～2016年6月30日)

CQ53 : 肝移植後の有効な再発予防法は何か? [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN or (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 LIVER TRANSPLANTATION+NT/CT OR LIVER+NT/CT(L)TR/CT OR LIVER?(3A)TRANSPLANT?
- L11 RECURREN?
- L12 NEOPLASM RECURRENCE, LOCAL+NT/CT(L)PC/CT
- L13 (PROGRES? OR RECURREN?)(3A)(PREVEN? OR PROPHYLA?)
- L14 IMMUNOSUPPRESSIVE AGENTS+NT/CT(L)TU/CT

- L15 SURVIV?(3A)(INCREAS? OR PROLONG? OR IMPROV?)
- L16 (PREDICT? OR DETECT?)(3A)(PROGRES? OR RECURREN?)
- L17 USEFUL? OR EFFECTIVE? OR EFFICAC?
- L18 TREATMENT OUTCOME+NT/CT
- L19 L9 and L10 and L11
- L20 L19 and (L12 or L13)
- L21 L19 and (L14 or L15 or L16)
- L22 L21 and (L17 or L18 or L15/TI)
- L23 L20 or L22
- L24 *LIVER TRANSPLANTATION+NT/CT OR LIVER TRANSPLANTATION+NT/CT(L)MT/CT OR TRANSPLANT?/TI
- L25 L24 and L23

CQ54 : 肝切除後・穿刺局所療法後の再発に対する有効な治療法は何か？ [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL# or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN or (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 and PY=>2011 AND UP=20120101-20160630 not epub?/fs
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 HEPATECTOMY+NT/CT
- L11 LIVER NEOPLASMS+NT/CT(L)SU/CT
- L12 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI
- L13 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)(4A)(AFTER OR FOLLOW?)
- L14 POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST()(SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)
- L15 (L13 or L14)(4A)RECURREN?
- L16 L9 and (L10 or L11 or L12)
- L17 L15 and L16
- L18 NEOPLASM RECURRENCE, LOCAL+NT/CT(L)(TH or DT or RT or SU)/CT
- L19 L17 and L18
- L20 L15/TI and L17

L21 QUE (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN?
OR SUPERIOR?)/TI

L22 L20 AND L21

L23 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR
SUPERIOR?)(5A)L15

L24 L20 and L23

L25 RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL+NT/CT

L26 QUE TU/CT

L27 L20 and L25 and L26

L28 L19 and L15/TI

L29 L19 or L22 or L24 or L27 or L28

L30 (PEI OR PEIT OR EIT) AND ETHANOL##

L31 MICROWAVES/CT OR MICROWAVE?(3A)(PERCUTAN? OR COAGULAT?)

L32 (PMCT OR MCT) AND MICROWAVE?

L33 ELECTROCOAGULATION+NT/CT OR RADIO WAVES/CT OR ABLAT?

L34 RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA

L35 PEI and (PERCUTANEOUS? or ETHANOL?) or PEIT or (PERCUTANEOUS? or
TRANSDERMAL?)(2A)(ETHANOL? OR ETHYL()ALCOHOL?)

L36 PMCT or PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?

L37 RFA or (RADIO(1W)(FREQUENC? or WAVE?) or RADIOFREQUEN?)(2A)ABLAT?

L38 (LOCAL or TOPICAL or LOCOREGIONAL? OR LOCO()REGIONAL?)(3A)(REMEDI? or THERAP? or
TREATMENT? or CENTESIS or NEEDL? or NYXIS or PUNCTURE? or ACUPUNCTURE?)

L39 L30-L38

L40 L9 and L39

L41 (PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR
RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?)(4A)(AFTER
OR FOLLOW?)

L42 POST()(RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL? OR
TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)

L43 (L41 or L42)(4A)RECURREN?

L44 L40 and L43

L45 L18 and L44

L46 L21 and L44

L47 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR
SUPERIOR?)(4A)L43

L48 L44 and L47

L49 L25 AND L26 AND L44

L50 (AFTER OR FOLLOW?)(1W)(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE?
OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL?
OR TOPICAL?)

L51 RECURREN?(3W)L50

- L52 L51 and L44 and (L18 or L21)
- L53 L45 or L46 or L48 or L49 or L52
- L54 L29 OR L53

CQ55 : 肝移植後の再発に対する有効な治療法は何か？ [MEDLINE]

- L1 CARCINOMA, HEPATOCELLULAR/CT or (HEPATOCELL? or HAEPATOCELL? or (HEPATO? or HAEPATO? or LIVER?)(W)(CELL## or CELLULA?))(2A)(NEOPLASM? or CANCER? or TUMOR? or TUMOUR? or CARCINOM?)/TI or (HEPATOMA# or HAEPATOMA#)/TI or (HCC or HCCS)/TI and LIVER NEOPLASMS+NT/CT
- L2 L1/HUMAN or (L1 NOT ANIMALS)
- L3 L2/ENG
- L4 L3 and PY=>2011 and UP=20120101-20160630 NOT EPUB?/FS
- L5 QUE REVIEW?/DT OR REVIEW?/TI OR CASE REPORT?/DT OR CASE()REPORT?/TI
- L6 L4 NOT L5
- L7 QUE META-ANALYSIS/DT OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC(1W)REVIEW?/TI OR PRACTICE GUIDELINE/DT OR PRACTICE GUIDELINES AS TOPIC+NT/CT
- L8 L4 and L7
- L9 L6 or L8
- L10 LIVER TRANSPLANTATION+NT/CT OR LIVER+NT/CT(L)TR/CT OR LIVER?(3A)TRANSPLANT?
- L11 L9 and L10
- L12 NEOPLASM RECURRENCE, LOCAL+NT/CT(L)(TH or DT or RT or SU)/CT
- L13 RECURREN?(4A)((FOLLOW? OR AFTER)(4A)TRANSPLAN? OR POSTTRANSPLAN? OR POST()TRANSPLAN?)
- L14 L11 and L12
- L15 L11 and L13/TI
- L16 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI
- L17 L15 AND L16
- L18 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(5A)L13
- L19 L18 and L11
- L20 RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL+NT/CT
- L21 TU/CT
- L22 L11 and L20 and L21
- L23 L14 or L17 or L19 or L22